Skip to main content

LIVE

EXOZ

eXoZymes, Inc.

EXOZ

NASDAQ·Healthcare·Biotechnology·Mkt cap $63.6M

$6.85

+0.74%

P/E

-5.71

Mkt Cap

$63.6M

52-Wk Range

$4.35–$18.40

52-Week Range

$4.35 - $18.40

P/E

-5.71

Fwd P/E

Beta

3.15

Div Yield

0.00%

Avg Vol

7.6K

Shares Out

8.5M

Mkt Cap

$63.6M

Price action

Price chart

Down 42.9% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary SimplePath enzymatic platform enabling modular biocatalytic conversions
  • Cost and sustainability advantages over traditional chemical synthesis methods
  • Diversified application portfolio across multiple high-value industries
  • Intellectual property protection through patents in synthetic biology and enzyme engineering

Bear Case

1 risk

  • Very high volatility (beta 3.1). Expect 3x market swings. Position size accordingly.

Growth

No forward estimates available

Increasing demand for sustainable and eco-friendly chemical manufacturing

Value

Valuation data unavailable

Momentum

Falling

-20.5% over 3m

Quality

Loss-making

Below average quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Q3 26 RECAP

AUG 13, 2026

Most recent quarter reported revenue of $0. Reported EPS of -$0.33.

Reported EPS · last 4Q

0 of 1 beats

Q3 26

Revenue trend · last 8Q

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

vs Industry

How EXOZ stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.